SCHEMBL6307794

SCHEMBL6307794

COc1ccc(S(=O)(=O)N[C@@H]2CCC[C@H]2N2CCC(Cc3ccc(Cl)cc3)CC2)cc1OC

nearest known ligand 0.55

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ CRHBP P24387 6/20 0.55
▸ CRHR2 Q13324 6/20 0.55
▸ KMT2A Q03164 1/20 0.52
▸ MCOLN3 Q8TDD5 7/20 0.50
▸ PDE4A P27815 2/20 0.48
▸ PDE4B Q07343 2/20 0.48
▸ PDE4C Q08493 2/20 0.48
▸ PDE4D Q08499 2/20 0.48
▸ MCOLN2 Q8IZK6 6/20 0.47
▸ MCOLN1 Q9GZU1 6/20 0.47
▸ ALDH1A1 P00352 1/20 0.47
▸ TP53 P04637 1/20 0.47
▸ GAA P10253 1/20 0.45
▸ MAPK1 P28482 1/20 0.43
▸ SMN1; SMN2 Q16637 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6307792 1.00 CRHBP (0.55) CRHBPCRHR2KMT2AMCOLN3PDE4A
SCHEMBL6306235 0.87 CRHBP (0.64) CRHBPCRHR2KMT2AMCOLN3MCOLN2
SCHEMBL6306239 0.87 CRHBP (0.64) CRHBPCRHR2KMT2AMCOLN3MCOLN2
SCHEMBL6305458 0.86 CRHBP (0.54) CRHBPCRHR2KMT2AMCOLN3MCOLN2
SCHEMBL6305460 0.86 CRHBP (0.54) CRHBPCRHR2KMT2AMCOLN3MCOLN2
SCHEMBL6306745 0.85 CRHBP (0.54) CRHBPCRHR2KMT2AMCOLN3MCOLN2
SCHEMBL6306743 0.85 CRHBP (0.54) CRHBPCRHR2KMT2AMCOLN3MCOLN2
SCHEMBL6310219 0.85 CRHBP (0.51) CRHBPCRHR2KMT2AMCOLN3MCOLN2
SCHEMBL6310216 0.85 CRHBP (0.51) CRHBPCRHR2KMT2AMCOLN3MCOLN2
SCHEMBL6310948 0.84 KMT2A (0.62) CRHBPCRHR2KMT2AMCOLN3MCOLN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6977265-B2 Piperidine CCR-3 receptor antagonists ROCHE PALO ALTO LLC (US) 2005-12-20 — — US disclosed
US-20030229121-A1 Piperidine CCR-3 receptor antagonists SYNTEX (U.S.A.) LLC 2003-12-11 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030229121-A1 Piperidine CCR-3 receptor antagonists CCR1, CCR3, CCRL2 CRHBP 1470/4885CRHR2 185/4885KMT2A 3093/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback